治疗阿尔茨海默病的药物：最好避免使用。没有治疗优势。
Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.
出版信息
Prescrire Int. 2012 Jun;21(128):150.
PMID:22822592
Abstract
The French Pharmacoeconomic Committee that assesses the medical benefit of new drugs and provides recommendations about reimbursement has downgraded its rating of the medical benefit (SMR, service mddical rendu) provided by cholinesterase inhibitors and memantine in Alzheimer's disease from "major" to "low".
摘要
评估新药医疗效益并提供报销建议的法国药物经济学委员会，已将胆碱酯酶抑制剂和美金刚在阿尔茨海默病中所提供的医疗效益评级（SMR，医疗服务产出）从“重大”降至“低”。
Zotero 插件